www.breakingviews.com
With the major pharmaceuticals companies facing up to a bloated cost structure and the legacy of two decades of underinvestment, the biotechnology industry is more or less guaranteed to outgrow the big drugs firms because of it structure.
Last year was awful for big pharma, with big US companies lagging the S&P500 by 28%. This has left the sector trading at the cheapest it has been relative to the market as a whole in 10 years. This is not a temporary affair. It is the result of big pharma focusing on marketing at the expense of developing new drugs. The number of new drugs approved in 2004 is about the same as in 1985. Yet the cost base has grown sharply over this time. The average big pharma company now spends about 32% of its budget on sales and marketing, roughly the same as companies selling soda...
This is archived content. Your current settings does not currently allow access to the archive. To gain access visit the subscription page or call our hotline on +44 (0)207 779 8999.
If you are a trialist or subscriber, please enter your username and password at the top right-hand side of euromoney.com
Subscribers to Euromoney benefit from:
Level 1:
- Online access to the past 12 months content
- Tailored RSS news feeds direct to your desktop
- News delivered directly to your mobile device or PC
- Personalised email newsfeed of 'Top stories' and 'Breaking news'
Level 2:
- Exclusive access to euromoney.com - Read the latest issue early online, search for specific developments by region or sector, interrogate the results of Euromoney's benchmark polls, and view the archive dating back to 2000
- 12 monthly issues of Euromoney magazine
- More than 30 specialist research guides free
- The results of Euromoney’s polls and surveys
- Tailored RSS news feeds direct to your desktop
- News delivered directly to your mobile device or PC
- Personalised email newsfeed of 'Top stories' and 'Breaking news'
Click here to subscribe